• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Improvement of a SARS-CoV-2 vaccine by enhancing the conjugation efficiency of the immunogen to self-assembled nanoparticles.

作者信息

Zhang Xiantao, Yuan Yaochang, Wu Bolin, Wang Xuemei, Lin Yingtong, Luo Yuewen, Li Rong, Chen Tao, Deng Jieyi, Zhang Xu, Zou Fan, He Xin, Zhang Hui

机构信息

Institute of Human Virology, Key Laboratory of Tropical Disease Control of the Ministry of Education, Guangdong Engineering Research Center for Antimicrobial Agents and Immunotechnology, Engineering Research Center of Gene Vaccines of the Ministry of Education, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, 510080, Guangdong, China.

Qianyang Biomedical Research Institute, Guangzhou, Guangdong, 510063, China.

出版信息

Cell Mol Immunol. 2021 Aug;18(8):2042-2044. doi: 10.1038/s41423-021-00736-2. Epub 2021 Jul 19.

DOI:10.1038/s41423-021-00736-2
PMID:34282299
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8287548/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb56/8322412/e3335bcc90db/41423_2021_736_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb56/8322412/e3335bcc90db/41423_2021_736_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb56/8322412/e3335bcc90db/41423_2021_736_Fig1_HTML.jpg

相似文献

1
Improvement of a SARS-CoV-2 vaccine by enhancing the conjugation efficiency of the immunogen to self-assembled nanoparticles.通过提高免疫原与自组装纳米颗粒的偶联效率来改进新冠病毒疫苗。
Cell Mol Immunol. 2021 Aug;18(8):2042-2044. doi: 10.1038/s41423-021-00736-2. Epub 2021 Jul 19.
2
Comparative Immunomodulatory Evaluation of the Receptor Binding Domain of the SARS-CoV-2 Spike Protein; a Potential Vaccine Candidate Which Imparts Potent Humoral and Th1 Type Immune Response in a Mouse Model.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突蛋白受体结合域的比较免疫调节评估；一种在小鼠模型中可引发强效体液免疫和Th1型免疫反应的潜在疫苗候选物
Front Immunol. 2021 May 24;12:641447. doi: 10.3389/fimmu.2021.641447. eCollection 2021.
3
Stabilization of the SARS-CoV-2 Spike Receptor-Binding Domain Using Deep Mutational Scanning and Structure-Based Design.利用深度突变扫描和基于结构的设计稳定 SARS-CoV-2 刺突受体结合结构域。
Front Immunol. 2021 Jun 29;12:710263. doi: 10.3389/fimmu.2021.710263. eCollection 2021.
4
Recombinant chimpanzee adenovirus AdC7 expressing dimeric tandem-repeat spike protein RBD protects mice against COVID-19.表达二聚体串联重复刺突蛋白 RBD 的重组黑猩猩腺病毒 AdC7 可保护小鼠免受 COVID-19 侵害。
Emerg Microbes Infect. 2021 Dec;10(1):1574-1588. doi: 10.1080/22221751.2021.1959270.
5
Induction of Potent and Durable Neutralizing Antibodies Against SARS-CoV-2 Using a Receptor Binding Domain-Based Immunogen.基于受体结合域的免疫原诱导针对 SARS-CoV-2 的强效和持久中和抗体
Front Immunol. 2021 Mar 11;12:637982. doi: 10.3389/fimmu.2021.637982. eCollection 2021.
6
A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge.一种基于人体细胞的 SARS-CoV-2 疫苗可引发强烈的中和抗体反应，并可保护小鼠免受 SARS-CoV-2 攻击。
Emerg Microbes Infect. 2021 Dec;10(1):1555-1573. doi: 10.1080/22221751.2021.1957400.
7
A Novel DNA Vaccine Against SARS-CoV-2 Encoding a Chimeric Protein of Its Receptor-Binding Domain (RBD) Fused to the Amino-Terminal Region of Hepatitis B Virus preS1 With a W4P Mutation.一种新型针对 SARS-CoV-2 的 DNA 疫苗，编码一种嵌合蛋白，由其受体结合域（RBD）与乙型肝炎病毒前 S1 区的氨基末端融合，该嵌合蛋白带有 W4P 突变。
Front Immunol. 2021 Feb 26;12:637654. doi: 10.3389/fimmu.2021.637654. eCollection 2021.
8
Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents.鼻腔内递送 MVA 载体疫苗可在啮齿动物中诱导针对 SARS-CoV-2 的有效肺部免疫。
Front Immunol. 2021 Nov 11;12:772240. doi: 10.3389/fimmu.2021.772240. eCollection 2021.
9
Development of an inactivated vaccine candidate for SARS-CoV-2.SARS-CoV-2 灭活疫苗候选物的研发。
Science. 2020 Jul 3;369(6499):77-81. doi: 10.1126/science.abc1932. Epub 2020 May 6.
10
Immunogenicity of intranasal vaccine based on SARS-CoV-2 spike protein during primary and booster immunizations in mice.基于 SARS-CoV-2 刺突蛋白的鼻内疫苗在小鼠初次和加强免疫中的免疫原性。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2364519. doi: 10.1080/21645515.2024.2364519. Epub 2024 Jun 16.

引用本文的文献

1
Study on immunogenicity of recombinant ferritin hemagglutinin of canine distemper virus.犬瘟热病毒重组铁蛋白血凝素免疫原性研究
Virol J. 2025 Jul 28;22(1):260. doi: 10.1186/s12985-025-02802-x.
2
Development of T follicular helper cell-independent nanoparticle vaccines for SARS-CoV-2 or HIV-1 by targeting ICOSL.通过靶向ICOSL开发用于SARS-CoV-2或HIV-1的非T滤泡辅助细胞依赖性纳米颗粒疫苗。
NPJ Vaccines. 2024 Sep 28;9(1):176. doi: 10.1038/s41541-024-00971-4.
3
Overcoming Antigen Escape and T-Cell Exhaustion in CAR-T Therapy for Leukemia.

本文引用的文献

1
Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses.基于 SARS-CoV-2 受体结合域（RBD）和七肽重复（HR）的纳米颗粒疫苗可诱导出强大的保护性免疫应答。
Immunity. 2020 Dec 15;53(6):1315-1330.e9. doi: 10.1016/j.immuni.2020.11.015. Epub 2020 Nov 25.
2
Dual-targeting nanoparticle vaccine elicits a therapeutic antibody response against chronic hepatitis B.双靶向纳米颗粒疫苗引发针对慢性乙型肝炎的治疗性抗体应答。
Nat Nanotechnol. 2020 May;15(5):406-416. doi: 10.1038/s41565-020-0648-y. Epub 2020 Mar 2.
3
A pneumonia outbreak associated with a new coronavirus of probable bat origin.
克服 CAR-T 疗法治疗白血病中的抗原逃逸和 T 细胞耗竭。
Cells. 2024 Sep 23;13(18):1596. doi: 10.3390/cells13181596.
4
Development of a PCSK9-targeted nanoparticle vaccine to effectively decrease the hypercholesterolemia.开发一种针对 PCSK9 的纳米疫苗，以有效降低高胆固醇血症。
Cell Rep Med. 2024 Jun 18;5(6):101614. doi: 10.1016/j.xcrm.2024.101614.
5
Development of nanobodies targeting hepatocellular carcinoma and application of nanobody-based CAR-T technology.针对肝癌的纳米抗体的开发及基于纳米抗体的 CAR-T 技术的应用。
J Transl Med. 2024 Apr 12;22(1):349. doi: 10.1186/s12967-024-05159-x.
6
The construction of modular universal chimeric antigen receptor T (MU-CAR-T) cells by covalent linkage of allogeneic T cells and various antibody fragments.通过同种异体T细胞与各种抗体片段的共价连接构建模块化通用嵌合抗原受体T（MU-CAR-T）细胞。
Mol Cancer. 2024 Mar 11;23(1):53. doi: 10.1186/s12943-024-01938-8.
7
An Overview of Recent Developments in the Application of Antigen Displaying Vaccine Platforms: Hints for Future SARS-CoV-2 VLP Vaccines.抗原展示疫苗平台应用的最新进展综述：对未来新冠病毒样颗粒疫苗的启示
Vaccines (Basel). 2023 Sep 20;11(9):1506. doi: 10.3390/vaccines11091506.
8
A Mosaic Nanoparticle Vaccine Elicits Potent Mucosal Immune Response with Significant Cross-Protection Activity against Multiple SARS-CoV-2 Sublineages.一种镶嵌型纳米颗粒疫苗可引发强烈的黏膜免疫应答，并对多种 SARS-CoV-2 亚谱系具有显著的交叉保护活性。
Adv Sci (Weinh). 2023 Sep;10(27):e2301034. doi: 10.1002/advs.202301034. Epub 2023 Aug 1.
9
A tetravalent nanoparticle vaccine elicits a balanced and potent immune response against dengue viruses without inducing antibody-dependent enhancement.一种四价纳米颗粒疫苗可引发针对登革热病毒的平衡且有效的免疫应答，而不会诱导抗体依赖性增强作用。
Front Immunol. 2023 May 19;14:1193175. doi: 10.3389/fimmu.2023.1193175. eCollection 2023.
10
Development of Receptor Binding Domain (RBD)-Conjugated Nanoparticle Vaccines with Broad Neutralization against SARS-CoV-2 Delta and Other Variants.研发针对 SARS-CoV-2 德尔塔及其他变体具有广谱中和作用的受体结合域（RBD）偶联纳米颗粒疫苗。
Adv Sci (Weinh). 2022 Apr;9(11):e2105378. doi: 10.1002/advs.202105378. Epub 2022 Feb 10.
一种新型冠状病毒引发的肺炎疫情，该病毒可能来源于蝙蝠。
Nature. 2020 Mar;579(7798):270-273. doi: 10.1038/s41586-020-2012-7. Epub 2020 Feb 3.
4
Engineering a Rugged Nanoscaffold To Enhance Plug-and-Display Vaccination.工程化坚固纳米支架以增强即插即用型疫苗接种。
ACS Nano. 2018 Sep 25;12(9):8855-8866. doi: 10.1021/acsnano.8b02805. Epub 2018 Jul 26.
5
Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin.通过工程化设计一种细菌黏附素，形成一个快速共价键的肽标签与蛋白质结合。
Proc Natl Acad Sci U S A. 2012 Mar 20;109(12):E690-7. doi: 10.1073/pnas.1115485109. Epub 2012 Feb 24.
6
NMR spectroscopic and theoretical analysis of a spontaneously formed Lys-Asp isopeptide bond.对自发形成的赖氨酸-天冬氨酸异肽键的核磁共振光谱和理论分析。
Angew Chem Int Ed Engl. 2010 Nov 2;49(45):8421-5. doi: 10.1002/anie.201004340.